MORRISTOWN, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Graham Miao, Ph.D., President and Chief Financial Officer (CFO), will leave the Company at the end of the year in order to pursue other opportunities. Pernix will immediately begin a search to identify a successor to Dr. Miao, who will provide support to the Company during a transition period. Dr. Miao’s resignation does not reflect any disagreement with the Company's financial results or strategy for growth.

Dr. Miao has served as President and CFO of Pernix since July 2016. Prior to this, he served as a senior advisor to the Chief Executive Officer (CEO) and Board of Directors of Pernix from May 2016.

“I would like to thank Graham for his dedication to the Company and wish him success in his future endeavors,” said John Sedor, Chairman and CEO of Pernix Therapeutics. “As a result of our recently announced refinancing transactions that helped strengthen our balance sheet, Pernix is now positioned to pursue additional growth opportunities.”

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Neurology and Pain, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.